RxDoctor Payments Data

Keli Layton-Cunnigan, PA

Physician Assistant · Moreno Valley, CANPI 1063613958

Payments from drug & device makers

$476in general payments, 2019–2025

Across 18 payments — averaging $26.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$233
  • Pfizer$79
  • Biohaven Pharmaceutical Holding Company Ltd.$39
  • Novo Nordisk$30
  • IBSA Pharma Inc.$23
  • AstraZeneca$23
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK6$233
Pfizer3$79
Biohaven Pharmaceutical Holding Company Ltd.2$39
Novo Nordisk2$30
IBSA Pharma Inc.1$23
AstraZeneca1$23
AbbVie1$19
Lilly USA, LLC1$19
Linus Health, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$476 in reported general payments places this provider in the 60th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$29,847
Medicare patients
216
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$12,911
JardianceEmpagliflozin12$11,803
Celecoxib11$1,340
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,238
Albuterol Sulfate HfaAlbuterol Sulfate50$1,071
Atorvastatin Calcium98$905
Fluticasone Propionate55$789
Levothyroxine Sodium42$571
Losartan Potassium74$561
Rosuvastatin Calcium24$482
Metoprolol Succinate13$442
Metformin Hcl44$440
Duloxetine Hcl16$437
Lisinopril41$322
Simvastatin37$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$12,91111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Moreno Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →